Advertisement
Advertisement
TOPIC
 / company

Eli Lilly

Eli Lilly
The latest news and top stories on Eli Lilly. An Indianapolis, Indiana-based entity in the pharmaceutical sector, Eli Lilly specialises in discovering, developing and manufacturing prescription drugs. It primarily serves healthcare providers and patients worldwide and is known for its pioneering work in insulin and the polio vaccine.
AstraZeneca’s booth at the China International Supply Chain Expo in Beijing, July 17, 2025. Photo: EPA
Made in China 2025

Global drug giants double down on China amid push for self-reliant supply chains

Multinationals are building self-reliant supply chains in China to insulate local markets from potential trade disruptions, say analysts.

China’s private sector

US reshoring drive casts shadow over China’s contract drug makers, analyst says

China’s private sector

Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain

Crime in Hong Kong

Hong Kong woman, 30, arrested over illegal sale of slimming injection

Seized item was Mounjaro injection pen manufactured by US pharmaceutical company Eli Lilly, but labelled in Japanese.

The seized item was a Mounjaro injection pen manufactured by US pharmaceutical company Eli Lilly, Photo: ISD
Made in China 2025

China biotech outlicensing tops US$52 billion in first 2 months

The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.

Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

Advertisement
Advertisement
Advertisement
China’s private sector

Wave of Chinese biotech deals builds with US$1.2 billion Harbour BioMed pact

Deal involving an antibody asset ‘goes beyond a traditional licensing transaction’, founder and CEO says.

Harbour BioMed’s antibody programme focuses on tumour-killing effects. Photo: Handout
Banking & finance

Mainland China’s investors pour into Hong Kong-listed drug stocks

An index tracking Stock Connect buying of 40 mainland drug firms gains 9 per cent in a week as China’s industry heft grows.

Biomedicine: Industry Trends

China could approve first AI-designed drug next year, Merck executive says

AI and genetics are creating a ‘seismic shift’ in the pharmaceutical business, experts on Asian Financial Forum panel say.

Hong Kong healthcare and hospitals

Explainer | Worth the weight? What Hongkongers should know about slimming injections

Department of Health says prescription-only injections can only be sold in pharmacies under supervision of registered pharmacists.

An investigation by the Post has found retailers offering weight-loss needles without prescriptions. Photo: SCMP
Hong Kong healthcare and hospitals

Exclusive | No prescription, no problem: Hong Kong’s grey zone for weight-loss injections

Slimming injections cannot be sold or purchased in Hong Kong without doctor’s prescription, but some retailers are operating grey market.

Weight-loss injections, which have been approved by Hong Kong authorities for use, have become increasingly popular around the world. Photo: Karma Lo
Wellness

Weight rebound after stopping Ozempic, Wegovy? Not necessarily, new data says

New research suggests that many people who stop using GLP-1 drugs like Ozempic maintain their weight loss, countering previous studies.

Made in China 2025

Exclusive | China challenges US in AI drug race, but rivals still reliant on each other

While US biotech firms increase use of Chinese clinical data, Chinese firms need US counterparts for monetisation, investor and scientist says.

Made in China 2025

Novartis, SciNeuro deal offers hope for 55 million suffering from Alzheimer’s

SciNeuro’s anti-amyloid programme is one of the firm’s key strategic research and development priorities to target the brain disease.

videocam
Swiss drugmaker Novartis has gained global rights over SciNeuro’s novel amyloid beta targeted antibody programme. Photo: Reuters
Made in China 2025

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.

There were more than 400 million overweight or obese adults in China in 2021, according to a study. Photo: Getty Images
Made in China 2025

Meow or never: China’s pudgy pets spark race for weight-loss drugs

Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.

IPO

China vital to Insilico’s plan to build biotech’s AI ‘Einstein’ for new drugs

US firm, backed by Fosun and Tencent, expands research base in China as it develops an AI-powered drug-discovery tool.

Advertisement
Advertisement
Advertisement
IPO

Insilico Medicine leads 6 Hong Kong IPOs, capping banner fundraising year

Debutants raise total of US$899 million as exchange wraps up one of the most active months for IPOs since 2021.

Executives of the six companies celebrate their listings in a gong ceremony at Hong Kong Exchanges and Clearing in Central on December 30, 2025. Photo: Sun Yeung
India

As India’s US$70 million obesity drug market bulges, so does price war

Pharmaceutical giants like Lilly and Nordisk are battling for dominance in India’s weight-loss market with price cuts and early launches.

videocam
Medicine

No need for needles? US approves Wegovy pill for weight loss

Novo Nordisk’s daily medication offers an oral alternative to blockbuster injections, with a launch expected in early January.

Made in China 2025

China’s new drug insurance: lifeline for patients or squeeze on big firms?

New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.

The commercial insurance formulary covers some medicines that are not yet eligible for reimbursement under the country’s National Reimbursement Drug List. Photo: Shutterstock
Banking & finance

3SBio spin-off Mandi banks on hair-loss and weight-loss drugs in Hong Kong IPO

As 3SBio lines up a Hong Kong spin-off for its hair-loss unit Mandi, the subsidiary is preparing a drug pipeline aimed at acne and obesity.

The spin-off would result in 3SBio completely exiting its stake in Mandi. Photo: SMCP
Wellness

How Ozempic and GLP-1 meds are reshaping wellness resort offerings

As more people turn to GLP-1s to manage their health and weight, wellness resorts are fine-tuning their offerings to support users.

Wellness

New weight-loss jab may help keep obesity at bay, researchers say

A study showed mice given new drug RES-10 lost weight and kept it off. Now, researchers hope it can help humans when injected once a week.

China Future Tech briefing

Biomedicine | China makes strides in brain-computer interface tech race

US and Chinese start-ups vie to commercialise tech that would transform the lives of amputees, the disabled and neurodegenerative disease patients.

China makes strides in brain-computer interface tech race
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement